SCHEMBL17890076

SCHEMBL17890076

COc1cc2nc(/C=C/c3ccc(F)cc3)nc(NCCCN3CCOCC3)c2cc1OC

nearest known ligand 0.77

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 11/20 0.77
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 1/20 0.61
MAPT P10636 1/20 0.61
MELK Q14680 1/20 0.60
TLR9 Q9NR96 1/20 0.53
KMT5A Q9NQR1 2/20 0.52
KDM1A O60341 1/20 0.50
EHMT2 Q96KQ7 1/20 0.50
RCOR1 Q9UKL0 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17890077 1.00 FLT3 (0.77) FLT3KDM4EALDH1A1MAPTMELK
SCHEMBL17890284 0.87 FLT3 (0.86) FLT3MELK
SCHEMBL17890281 0.87 FLT3 (0.86) FLT3MELK
SCHEMBL17890199 0.87 FLT3 (1.00) FLT3MELK
SCHEMBL17890201 0.87 FLT3 (1.00) FLT3MELK
SCHEMBL17890203 0.86 FLT3 (0.81) FLT3MELK
SCHEMBL17890200 0.86 FLT3 (0.81) FLT3MELK
SCHEMBL17890092 0.85 FLT3 (0.82) FLT3MELK
SCHEMBL17890090 0.85 FLT3 (0.82) FLT3MELK
SCHEMBL17890164 0.84 FLT3 (0.86) FLT3MAPTMELK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951029-B2 Styryl quinazoline derivatives as pharmaceutically active agents VICHEM CHEMIE KUTATÓ KFT. (HU) 2018-04-24 US disclosed
US-9951029-B2 Styryl quinazoline derivatives as pharmaceutically active agents VICHEM CHEMIE KUTATÓ KFT. (HU) 2018-04-24 US disclosed
US-9951029-B2 Styryl quinazoline derivatives as pharmaceutically active agents VICHEM CHEMIE KUTATÓ KFT. (HU) 2018-04-24 US disclosed
US-20160194291-A1 STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS VICHEM CHEMIE KUTATÓ KFT. (HU) 2016-07-07 US disclosed
US-20160194291-A1 STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS VICHEM CHEMIE KUTATÓ KFT. (HU) 2016-07-07 US disclosed
US-20160194291-A1 STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS VICHEM CHEMIE KUTATÓ KFT. (HU) 2016-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194291-A1 STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS FLT3, BCR, STK3 FLT3 1/4885KDM4E 4561/4885ALDH1A1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.